Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1992-09-28
1993-09-28
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 42, 514681, A61C 3170, A61C 3112
Patent
active
052486680
ABSTRACT:
Purpurogallin and its mono- and di-glucosides are useful as cytoprotective agents. Patient-administrable compositions for addition to a patient's blood to minimize oxyradical damage caused by ischemia-reperfusion injury that may result in various surgical procedures, and comprising purpurogallin or glucosides thereof, and uses thereof, are described.
REFERENCES:
patent: 4181545 (1990-01-01), Anderson
patent: 4647532 (1987-03-01), Watanabe
Chem Abst. 111(3):17704v of Jordan, PCT Int. Appl. WO 8803805 Jun. 2, 1988 Abstract only.
Merck Index, 11th Edition, entry No. 7963 1989.
Free Radical Research Communications, vol. 2, Nos. 1-2, 1986, Kontoghiorghes.
"Natural Immunity and Cell Growth Regulation", vol. 4, No. 5, Sep.-Oct. 1985 Leung.
Hook Gregory
Waddell Frederick E.
Wintek Consulting Ltd.
LandOfFree
Use of purpurogallin and glycosides thereof in treating ischemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of purpurogallin and glycosides thereof in treating ischemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of purpurogallin and glycosides thereof in treating ischemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2190957